CD177: A Potential Drug Target for Various Diseases (G57126)
CD177: A Potential Drug Target for Various Diseases
CD177 (CD177+) is a protein that is expressed in various tissues throughout the body, including the nervous system, gastrointestinal tract, and skin. It is a member of the immunoglobulin superfamily and is known for its role in cell signaling and inflammation.
CD177 has been identified as a potential drug target (NB1 GP) due to its involvement in various biological processes that are relevant to human disease, including cancer, neurodegenerative diseases, and autoimmune disorders.
CD177 has been shown to play a role in cancer progression by promoting the growth and survival of cancer cells. In addition, CD177 has been linked to the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
CD177 has also been shown to be involved in the regulation of immune responses, which could make it a promising target for interventions aimed at treating autoimmune disorders.
The search for potential drug targets is an ongoing process in the pharmaceutical industry, and the identification of CD177 as a potential NB1 GP has generated a lot of interest and excitement among researchers and pharmaceutical companies.
CD177 is a protein that can be targeted with small molecules, antibodies, or other therapeutic agents. Some studies have shown that CD177 can be effectively targeted with small molecules, such as inhibitors of the PI3K/Akt signaling pathway, which is a known regulator of CD177 function.
In addition, antibodies have also been shown to be effective targets for CD177. For example, studies have shown that monoclonal antibodies (MCABs) targeting CD177 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
CD177 is also a protein that has been shown to play a role in the regulation of cell signaling pathways that are relevant to human disease. For example, studies have shown that CD177 is involved in the regulation of the NF-kappa-B signaling pathway, which is involved in inflammation and pain signaling.
In addition, CD177 has also been shown to play a role in the regulation of the TGF-β signaling pathway, which is involved in cell growth, differentiation, and survival.
CD177 has also been shown to be involved in the regulation of cellular processes that are relevant to cancer progression. For example, studies have shown that CD177 is involved in the regulation of the angiogenic gene expression that is responsible for the formation of new blood vessels that can support the growth and survival of cancer cells.
In conclusion, CD177 is a protein that has been shown to play a role in various biological processes that are relevant to human disease, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target has generated a lot of interest and excitement among researchers and pharmaceutical companies. Further studies are needed to fully understand the role of CD177 in these biological processes and to develop effective treatments for these diseases.
Protein Name: CD177 Molecule
Functions: In association with beta-2 integrin heterodimer ITGAM/CD11b and ITGB2/CD18, mediates activation of TNF-alpha primed neutrophils including degranulation and superoxide production (PubMed:21193407). In addition, by preventing beta-2 integrin internalization and attenuating chemokine signaling favors adhesion over migration (PubMed:28807980). Heterophilic interaction with PECAM1 on endothelial cells plays a role in neutrophil transendothelial migration in vitro (PubMed:17580308). However, appears to be dispensable for neutrophil recruitment caused by bacterial infection in vivo (PubMed:23461681). Acts as a receptor for the mature form of protease PRTN3 allowing its display at the cell surface of neutrophils (PubMed:17244676, PubMed:18462208). By displaying PRTN3 at the neutrophil cell surface, may play a role in enhancing endothelial cell junctional integrity and thus vascular integrity during neutrophil diapedesis (PubMed:23202369)
The "CD177 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD177 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B
